Aveo Oncology Inc. and Kyowa Kirin Co. Ltd. amended their 2006 license agreement so that Kyowa Kirin can buy back the non-oncology rights of tivozanib in Aveo territories, including the U.S. and the EU, while Aveo retains U.S. rights in cancer.

LONDON – It's the technology that keeps on giving, and the Heptares unit of Sosei Group Corp. has attracted a further partner to its G protein-coupled receptor (GPCR) platform, signing up Takeda Pharmaceutical Ltd., in a deal worth up to $1.2 billion.